CellSearch study
This article was originally published in The Gray Sheet
Executive Summary
Counting circulating tumor cells with J&J/Veridex's cancer diagnostic system before treatment can independently predict progression-free survival and overall survival rates in patients with metastatic breast cancer, according to a 177-patient trial led by Massimo Cristofanilli, MD, University of Texas, published in the Aug. 19 NEJM. The CellSearch system was 510(k) cleared in June and likely will be commercially available this fall, according to Veridex...